Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on X:
“Thoughtful discussion by Andrea Apolo on Nectin-4 biology in urothelial cancer.
She reminds us that breast cancer physicians have already taught us that T-DXd works after T-DM1 failure: same HER2 target, different payload (DESTINY-Breast02: PFS 17.8 vs 6.9 months, HR 0.36). The antibody isn’t doing all the work.
LY4052031 is testing the same logic in urothelial. Topo-I payload, same Nectin-4 target as EV.
SHR-A2102, another Nectin-4 Topo-I ADC, in MIBC.
The sequencing question from early stage to refractory metastatic disease may be focused on the payload.”
Other articles about Nectin-4 on OncoDaily.
